Amy Burroughs discusses the success of Terns Pharma and developing TERN-701 for CML, being acquired by Merck for $6.7 billion, and leadership learnings throughout her career

Interviewed by Sisterhood editorial board member Erika Smith, Amy Burroughs discusses joining Terns when it was not obvious and at a time when the company was going through a sad moment, and how the momentum started to turn as data for TERN-701 started becoming apparent. She describes her career, which included stops at large and small companies, and on the investing side at 5AM Ventures, and provides leadership lessons along the way.